Log in to search using one of your social media accounts:

 

New buzz about immunotherapy

Why is everyone so excited about CAR-T cancer therapy? And how long does it take to list a hazardous chemical in Canada?
Source: CBC | Health - Category: Consumer Health News Tags: News/Health Source Type: news

Related Links:

Authors: Aqbi HF, Tyutyunyk-Massey L, Keim RC, Butler SE, Thekkudan T, Joshi S, Smith TM, Bandyopadhyay D, Idowu MO, Bear HD, Payne KK, Gewirtz DA, Manjili MH Abstract Breast cancer patients who initially respond to cancer therapies often succumb to distant recurrence of the disease. It is not clear why people with the same type of breast cancer respond to treatments differently; some escape from dormancy and relapse earlier than others. In addition, some tumor clones respond to immunotherapy while others do not. We investigated how autophagy plays a role in accelerating or delaying recurrence of neu-overexpressing...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Ma J, Xu H, Wang S Abstract Lung cancer is the leading cause of cancer death worldwide due to its late diagnosis and poor outcome. Immunotherapy is becoming more and more encouraging and promising in lung cancer therapy. Myeloid-derived suppressor cells (MDSCs) are the main tumor suppressor factors, and the treatment strategy of targeting MDSCs is gradually emerging. In this review, we summarize what is currently known about the role of MDSCs in lung cancer. In view of the emerging importance of MDSCs in lung cancer, the treatment of targeting MDSCs will be useful to the control of the development and prog...
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
When patients with advanced solid tumors are treated with immune checkpoint inhibitors, only men get double the survival benefits seen with standard cancer therapies.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Publication date: June 2018 Source:Molecular Immunology, Volume 98 Author(s): David Urbanavicius, Tara Alvarez, Georgina K. Such, Angus P.R. Johnston, Justine D. Mintern A complex and multifaceted relationship exists between cancer and the immune system. Advances in our understanding of this relationship have resulted in significant clinical attention in the possibilities of cancer immunotherapy. Harnessing the immune system’s potent and selective destructive capability is a major focus of attempts to treat cancer. Despite significant progress in the field, cancer therapy still remains significantly deficient, with ...
Source: Molecular Immunology - Category: Allergy & Immunology Source Type: research
Tumor treatment is still complicated in the field of medicine. Tumor immunotherapy has been the most interesting research field in cancer therapy. Application of chimeric antigen receptor T (CAR-T) cell therap...
Source: Molecular Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
The primary treatment for high-grade non-muscle invasive bladder cancer (NMIBC) is based on surgery by transurethral resection of bladder tumor (TURBT), followed by intravesical immunotherapy with Bacillus Calmette-Guerin (BCG) to prevent recurrence and to reduce the tumor progression. However, BCG therapy shows several undesirable effects. The current treatment on NMIBC is doxorubicin (DOX), but with high toxicity. Our nanotechnology strategy was done through scaffolds for the NMIBC treatment: graphene oxide (GO) and a nanostructured lipid carrier (NLC). A GO hybrid for administration of DOX and small interfering RNA (siR...
Source: Journal of the Brazilian Chemical Society - Category: Chemistry Source Type: research
Publication date: Available online 30 April 2018 Source:Seminars in Cancer Biology Author(s): Tobias Gutting, Elke Burgermeister, Nicolai Härtel, Matthias P. Ebert Immunotherapy is the latest revolution in cancer therapy. It continues to show impressive results in malignancies like melanoma and others. At least so far, effects are modest in colorectal cancer (CRC) and only a subset of patients benefits from already approved checkpoint inhibitors. In this review, we discuss major hurdles of immunotherapy like the immunosuppressive niche and low immunogenicity of CRC next to current achievements of checkpoint inhibitor...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Authors: Wang R, Zhou T, Liu W, Zuo L Abstract Cancer cells subjected to ionizing radiation may release signals which can influence nearby non-irradiated cells, termed bystander effects. The transmission of bystander effects among cancer cells involves the activation of inflammatory cytokines, death ligands, and reactive oxygen/nitrogen species. In addition to bystander effects, two other forms of non-target effects (NTEs) have been identified in radiotherapy, as one is called cohort effects and the other is called abscopal effects. Cohort effects represent the phenomenon where irradiated cells can produce signals ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
We describe the evolution of response criteria with a special focus on the immune-related criteria. PMID: 29714647 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
Purpose of review Strong preclinical data support prophylactic probiotics as an effective preventive strategy for diarrhoea secondary to anticancer therapies. To determine the composite evidence that this approach translates to the clinic, we performed a meta-analysis of randomized controlled trials (RCTs) of prophylactic probiotics for the prevention of cancer therapy-induced diarrhoea. Recent findings A three-step search strategy was used to identify relevant studies (1 June 2000–1 June 2017) investigating probiotic intervention for diarrhoea secondary to any cancer therapy (cytotoxic, targeted and immunothera...
Source: Current Opinion in Supportive and Palliative Care - Category: Palliative Care Tags: GASTROINTESTINAL SYMPTOMS: Edited by Joanne M. Bowen and Nicole Blijlevens Source Type: research
More News: Canada Health | Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Health | Immunotherapy